Initiation of SSRIs was associated with increased fracture risk among middle-aged women, while other antidepressants were not linked to increased risks.

A phase 2 trial suggests that the novel SNRI ammoxetine may effectively treat major depressive disorder while avoiding some side effects common to other antidepressants.

Depression and anxiety disorders are among the most widespread mental health disorders, with estimates suggesting that they ...